<?xml version="1.0" ?>
<document id="f64d07df542245c19781c36476a6cde273627f87">
  <chunk id="f64d07df542245c19781c36476a6cde273627f87.c0" text="a section of the journal Frontiers in Cellular and Infection Microbiology Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria">
    <entity charOffset="74-78" id="f64d07df542245c19781c36476a6cde273627f87.c0.e0" ontology_id="CHEBI_23888" text="Drug" type="chemical"/>
    <entity charOffset="100-108" id="f64d07df542245c19781c36476a6cde273627f87.c0.e1" ontology_id="CHEBI_37943" text="Colistin" type="chemical"/>
  </chunk>
  <chunk id="f64d07df542245c19781c36476a6cde273627f87.c1" text="The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses.">
    <entity charOffset="69-80" id="f64d07df542245c19781c36476a6cde273627f87.c1.e0" ontology_id="CHEBI_33281" text="antibiotics" type="chemical"/>
    <entity charOffset="127-138" id="f64d07df542245c19781c36476a6cde273627f87.c1.e1" ontology_id="CHEBI_33281" text="antibiotics" type="chemical"/>
    <entity charOffset="334-344" id="f64d07df542245c19781c36476a6cde273627f87.c1.e2" ontology_id="CHEBI_46765" text="carbapenem" type="chemical"/>
    <entity charOffset="441-452" id="f64d07df542245c19781c36476a6cde273627f87.c1.e3" ontology_id="CHEBI_33281" text="antibiotics" type="chemical"/>
    <entity charOffset="471-475" id="f64d07df542245c19781c36476a6cde273627f87.c1.e4" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="653-657" id="f64d07df542245c19781c36476a6cde273627f87.c1.e5" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="867-871" id="f64d07df542245c19781c36476a6cde273627f87.c1.e6" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="888-898" id="f64d07df542245c19781c36476a6cde273627f87.c1.e7" ontology_id="CHEBI_46765" text="carbapenem" type="chemical"/>
    <entity charOffset="1046-1050" id="f64d07df542245c19781c36476a6cde273627f87.c1.e8" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="1100-1104" id="f64d07df542245c19781c36476a6cde273627f87.c1.e9" ontology_id="CHEBI_23888" text="drug" type="chemical"/>
    <entity charOffset="1157-1171" id="f64d07df542245c19781c36476a6cde273627f87.c1.e10" ontology_id="CHEBI_52217" text="pharmaceutical" type="chemical"/>
    <entity charOffset="1224-1229" id="f64d07df542245c19781c36476a6cde273627f87.c1.e11" ontology_id="CHEBI_23888" text="drugs" type="chemical"/>
    <entity charOffset="1357-1360" id="f64d07df542245c19781c36476a6cde273627f87.c1.e12" ontology_id="CHEBI_53218" text="MDR" type="chemical"/>
  </chunk>
</document>
